We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prognostic Marker Gene Found for Anaplastic Astrocytoma

By LabMedica International staff writers
Posted on 23 Jun 2015
Print article
Image: Histopathology of an anaplastic astrocytoma showing marked nuclear pleomorphism. Note the atypical mitosis in the center (Photo courtesy of Dr. Peter C. Burger, MD).
Image: Histopathology of an anaplastic astrocytoma showing marked nuclear pleomorphism. Note the atypical mitosis in the center (Photo courtesy of Dr. Peter C. Burger, MD).
A gene encoding for the enzyme isocitrate dehydrogenase 1 (IDH1) might be prognostic marker for a rare form of brain cancer known as anaplastic astrocytoma.

Astrocytomas arise from astrocytes, star-shaped cells that help nourish and support nerve and blood-vessel cells in the brain. Anaplastic astrocytomas are grade III brain tumors that can become grade IV tumors, which are also called glioblastoma.

Scientists at the Wexner Medical Center, Ohio State University (Columbus, OH, USA) carried out the IDH study as part of the phase III clinical trial Randomized Study of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (RTOG 9813), which involved 301 patients with anaplastic astrocytoma. The dual-arm trial evaluated the effectiveness of radiation therapy plus either of two chemotherapy drugs: temozolomide and nitrosourea.

The clinical trial showed no significant difference in survival in patients taking temozolomide compared with patients taking nitrosourea after a follow up of 3.6 years on average. However, the study also suggested a trend toward better survival for patients with mutated IDH who received radiation therapy plus temozolomide compared with patients receiving radiation therapy and nitrosourea. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH.

Treatment of anaplastic astrocytomas first requires surgery to remove as much tumor as possible. Complete removal is often impossible, however, because the tumors typically develop projections that extend into healthy brain tissue. Radiation therapy is then used to kill any remaining tumor cells. Chemotherapy is often recommended during or after radiation or both.

Arnab Chakravarti, MD, chair and professor of Radiation Oncology and director of the Brain Tumor Program at Ohio State University, and co-author of the study said, “We found that IDH status is not only a significant prognostic biomarker for the classification of anaplastic gliomas, but there appears to be an interesting trend in the data which suggests that it might also be an important predictive biomarker for determining which type of chemotherapy patients should receive. If this novel finding is verified, it could have a critical influence on future patient care.” The study was presented at the American Society of Clinical Oncology annual meeting held May 29–June 2, 2015, in Chicago (IL, USA).

Related Links:

Wexner Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.